Dare Bioscience, Inc. (DARE) is a prominent biotherapeutics company with the sole commitment to advancement in novel women’s health products. The company expands its treatment options in the areas of contraception, fertility, and vaginal health. XACIATO is the initial FDA-approved company’s product, which is a clear, viscous gel, administered intravaginally. The product portfolio of the company also includes Ovaprene, Sildenafil Cream, and DARE-HRT1.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
DARE stock price during the regular trading of March 30, 2022, was $1.47 with a plummeting of 1.34%. Its price swelled as of the writing in the premarket session of March 31, 2022, by 14.2%.
DARE: Key Financials
DARE disclosed its full fiscal year 2021 financial outcomes on March 31, 2022, for the year ended December 31, 2021. Some of the notable features are highlighted below.
No revenue was reported by the company for the comparable fiscal years 2021 and 2020.
Basic and diluted per share net loss in FY21 was $38.6 million or $0.63 in comparison to $27.4 million or $0.91 for fiscal 2020. The company’s net loss reduced considerably over the year.
DARE: Events and Happenings
On March 31, 2021, DARE reported its entry into a contract with Organon for the licensing of international rights to XACIATO, which is an FDA-approved medicine for treating bacterial vaginosis in females. Organon will give a $10 million upfront payment to the company.
On March 22, 2022, DARE announced its Executive management participated in the Maxim Group LLC Virtual 2022 Growth Conference held on March 28-30, 2022. On March 02, 2022, DARE stated its top management represented the company at the following conferences.
- Virtual Cowen 42ndAnnual Health Care Conference held on March 7-9.
- Virtual Therapeutic Area Partnerships: Accelerating Innovation in Women’s Health held on March 8-9, and
- 34thAnnual Roth Conference held on March 13-15, 2022.
DARE stock price is 29% down year-to-date and rocketed higher in Thursday’s premarket trading. The sole reason behind the price gain is its full-year 2021 earnings release and entry into a licensing and distribution agreement with Organon.